Tower Research Capital LLC (Trc) Recursion Pharmaceuticals, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 5,427 shares of RXRX stock, worth $50,362. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,427
Previous 4,811
12.8%
Holding current value
$50,362
Previous $31,000
16.13%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding RXRX
# of Institutions
339Shares Held
284MCall Options Held
2.83MPut Options Held
3.64M-
Vanguard Group Inc Valley Forge, PA34MShares$316 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.3MShares$300 Million1.91% of portfolio
-
Baillie Gifford & CO24.9MShares$231 Million0.13% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$161 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$136 Million0.44% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.67B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...